Please assess the completion status of the following clinical trial:

Trial Title: CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years~* History of gout - crystal proven or historical as defined by ACR criteria listed above~* Serum urate level \> 6.8 mg/dl~Exclusion Criteria:~* Stage 4 or 5 Chronic Kidney Disease (CKD) - defined as eGFR \< 30 ml/min/1.73 m2~* Women less than 50 years of age~* Patients with a history of prior solid organ / hematopoietic transplantation~* Previous allergy or intolerance to allopurinol or febuxostat~* Patients who are not candidates for any of the recommended prophylactic medications (colchicine, naprosyn or glucocorticoids)~* Patients who in the opinion of the investigator have a high genetic risk for allopurinol hypersensitivity syndrome (AHS\*) unless they have been found to be negative for HLA B5801.~* Previous history of failure to reach target uric acid levels despite therapy with allopurinol at dose \> 300 mg/day~* Prior febuxostat use~* Patients with malignancies that are currently active with exception of non-melanoma skin cancer~* Patients with serum uric acid levels \>15 mg/dl~* Patients with myelodysplasia and hemoglobin of \< 8.5 mg/dL~* Patients with chronic liver disease with more than one of the following:~  * INR \> 1.7, not on Warfarin therapy~ * Bilirubin 2 mg/dL~ * Serum albumin \< 3.5 mg/dL~ * Ascites~ * Encephalopathy~* Current use of azathioprine, mercaptopurine, didanosine, cyclophosphamide, probenecid, lesinurad or pegloticase~* Enrollment in another randomized interventional clinical trial~* Any severe medical condition that, in the enrolleer's opinion, is likely to compromise the participant's ability to complete the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allopurinol / Sham Comparator (Febuxostat) (Type: ACTIVE_COMPARATOR): Patients will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Febuxostat will be given with allopurinol
- Febuxostat / Sham Comparator (Allopurinol) (Type: ACTIVE_COMPARATOR): Febuxostat will be titrated up to the dose that will lower to target uric acid levels. A placebo resembling Allopurinol will be given with Febuxostat

Based on this trial design, predict the completion outcome and termination type (if applicable).